Literature DB >> 16214222

Alpha1-antitrypsin inhibits Moraxella catarrhalis MID protein-induced tonsillar B cell proliferation and IL-6 release.

Radinka Hadzic1, Izabela Nita, Helena Tassidis, Kristian Riesbeck, Anette Gjörloff Wingren, Sabina Janciauskiene.   

Abstract

Alpha1-antitrypsin (AAT) is a major circulating and tissues inhibitor of serine proteinases implicated in the regulation of inflammation and host defence. There is now increasing evidence that AAT may also exhibit anti-inflammatory activities independent of its protease inhibitor function. This study was undertaken to investigate the effects of native (inhibitory) and polymerized (non-inhibitory) forms of AAT on MID (Moraxella IgD binding protein)-induced human tonsillar B cell activation in vitro. We found that 0.5 microg/ml MID induces B cell proliferation and stimulates IL-6 release (p<0.001) relative to non-stimulated controls. Both native and polymerized AAT (0.5 mg/ml) inhibited MID-stimulated B cell proliferation in a similar manner (by 70%, p<0.001), whereas MID-induced IL-6 release was more strongly suppressed by polymerized (9.9-fold, p<0.001) as compared to native AAT (2.8-fold, p<0.01). Electrophoretic analysis of cell culture media did not indicate any interaction between AAT and MID, and flow cytometry data showed no competition for the same receptor. The effects of AATs were observed whether added together with MID or 2h after MID-addition to cell cultures. Thus, our data demonstrate that AAT inhibits MID-induced B cell activation in vitro that is unrelated to its protease inhibitory activity and is not dependent on MID binding to the cell surface.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16214222     DOI: 10.1016/j.imlet.2005.08.006

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  8 in total

1.  Alpha-1-antitrypsin phenotypes and neutrophil elastase gene promoter polymorphisms in lung cancer.

Authors:  Aleksandra Topic; Mila Ljujic; Aleksandra Nikolic; Natasa Petrovic-Stanojevic; Vesna Dopudja-Pantic; Marija Mitic-Milikic; Dragica Radojkovic
Journal:  Pathol Oncol Res       Date:  2010-06-03       Impact factor: 3.201

Review 2.  Expanding the clinical indications for α(1)-antitrypsin therapy.

Authors:  Eli C Lewis
Journal:  Mol Med       Date:  2012-09-07       Impact factor: 6.354

Review 3.  Acute-phase protein α1-anti-trypsin: diverting injurious innate and adaptive immune responses from non-authentic threats.

Authors:  O Guttman; B M Baranovski; R Schuster; Z Kaner; G S Freixo-Lima; N Bahar; N Kalay; M I Mizrahi; I Brami; D E Ochayon; E C Lewis
Journal:  Clin Exp Immunol       Date:  2015-02       Impact factor: 4.330

4.  The multiple facets of alpha-1-antitrypsin.

Authors:  Robert A Stockley
Journal:  Ann Transl Med       Date:  2015-06

Review 5.  Efficacy of alpha1-antitrypsin augmentation therapy in conditions other than pulmonary emphysema.

Authors:  Ignacio Blanco; Beatriz Lara; Frederick de Serres
Journal:  Orphanet J Rare Dis       Date:  2011-04-12       Impact factor: 4.123

6.  alpha1-Antitrypsin monotherapy induces immune tolerance during islet allograft transplantation in mice.

Authors:  Eli C Lewis; Mark Mizrahi; Michel Toledano; Nathaniel Defelice; Joanne L Wright; Andrew Churg; Leland Shapiro; Charles A Dinarello
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-13       Impact factor: 11.205

7.  Pancreatic islet xenograft survival in mice is extended by a combination of alpha-1-antitrypsin and single-dose anti-CD4/CD8 therapy.

Authors:  Efrat Ashkenazi; Boris M Baranovski; Galit Shahaf; Eli C Lewis
Journal:  PLoS One       Date:  2013-05-22       Impact factor: 3.240

8.  Inflammatory markers in chronic obstructive pulmonary disease patients with different α1 antitrypsin genotypes.

Authors:  Danielius Serapinas; Brigita Sitkauskiene; Raimundas Sakalauskas
Journal:  Arch Med Sci       Date:  2012-12-19       Impact factor: 3.318

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.